AIHealthcare

Enveda Biosciences is a privately held, clinical-stage biotechnology company using artificial intelligence, machine learning, metabolomics, mass spectrometry, robotics, and high-throughput biology to identify and characterize molecules produced by plants and other living organisms. Its platform is designed to translate nature’s chemical diversity into small-molecule medicines, with programs spanning immunology and inflammation, atopic dermatitis, asthma, obesity, fibrosis, metabolic disease, chronic pain, and neurosensory indications. The company reports that its platform can advance drug candidates approximately four times faster and at one-tenth the cost of traditional pharmaceutical discovery; these are company-reported claims rather than independently verified market metrics. Enveda’s market position is that of a well-funded, clinical-stage AI-enabled drug-discovery biotech specializing in natural-product chemistry, with a reported pipeline of 10 development candidates and a lead program, ENV-294, in Phase 1b testing for atopic dermatitis as of September 2025.